A biotechnology company focused on developing vaccines and immunotherapies, it gained significant attention for its COVID-19 vaccine candidate. Investors closely monitor its progress due to its potential in addressing global health challenges and its role in the competitive vaccine market.
3 members of Congress have disclosed 4 trades in Novavax, Inc. (NVAX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2021-01-06 | Kurt Schrader | sell | $1K – $15K |
| 2020-10-13 | Pat Roberts | sell | $1K – $15K |
| 2020-08-17 | Pat Roberts | buy | $1K – $15K |
| 2010-01-11 | JAMES B. RENACCI | sell | $3,414.40 |